{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T08:59:05Z","timestamp":1790499545373,"version":"4.1.0"},"reference-count":27,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,8,1]],"date-time":"2019-08-01T00:00:00Z","timestamp":1564617600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Immunopharmacology"],"published-print":{"date-parts":[[2019,8]]},"DOI":"10.1016\/j.intimp.2019.04.031","type":"journal-article","created":{"date-parts":[[2019,5,10]],"date-time":"2019-05-10T04:57:19Z","timestamp":1557464239000},"page":"94-97","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"special_numbering":"C","title":["Comparison between the efficacy of intralesional rituximab versus intralesional triamcinolone in the treatment refractory Pemphigus Vulgaris lesions: A randomized clinical trial"],"prefix":"10.1016","volume":"73","author":[{"given":"Fariba","family":"Iraji","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Farzaneh","family":"Danesh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gita","family":"Faghihi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amirhossein","family":"Siadat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fatemeh","family":"Mokhtari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahboobeh","family":"Talakoob","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hossein","family":"Hafezi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.intimp.2019.04.031_bb0005","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1038\/jid.2011.249","article-title":"Incidence, mortality and causes of death of patients with pemphigus in Taiwan","volume":"132","author":"Huang","year":"2012","journal-title":"J. Investig. Dermatol."},{"issue":"6","key":"10.1016\/j.intimp.2019.04.031_bb0010","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1111\/j.1365-4632.2004.02501.x","article-title":"Pemphigus: analysis of 1209 cases","volume":"44","author":"Chams-Davatchi","year":"2005","journal-title":"Int. J. Dermatol."},{"key":"10.1016\/j.intimp.2019.04.031_bb0015","series-title":"A Comprehensive Review on Pemphigus Vulgaris","author":"Handa","year":"2019"},{"issue":"2","key":"10.1016\/j.intimp.2019.04.031_bb0020","doi-asserted-by":"crossref","first-page":"505","DOI":"10.3181\/00379727-117-29622","article-title":"Demonstration of skin antibodies in sera of pemphigus vulgaris patients by indirect immunofluorescent staining","volume":"117","author":"Beutner","year":"1964","journal-title":"Proc. Soc. Exp. Biol. Med."},{"issue":"3","key":"10.1016\/j.intimp.2019.04.031_bb0025","doi-asserted-by":"crossref","first-page":"396","DOI":"10.7326\/0003-4819-92-3-396","article-title":"Pemphigus: current concepts","volume":"92","author":"Ahmed","year":"1980","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.intimp.2019.04.031_bb0030","doi-asserted-by":"crossref","DOI":"10.1038\/nrdp.2017.26","article-title":"Pemphigus","volume":"3","author":"Kasperkiewicz","year":"2017","journal-title":"Nat. Rev. Dis. Primers."},{"issue":"9","key":"10.1016\/j.intimp.2019.04.031_bb0035","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1001\/archderm.1977.01640090084013","article-title":"Immunosuppressants and prednisone in pemphigus vulgaris: therapeutic results obtained in 63 patients between 1961 and 1975","volume":"113","author":"Lever","year":"1977","journal-title":"Arch. Dermatol."},{"issue":"5","key":"10.1016\/j.intimp.2019.04.031_bb0040","doi-asserted-by":"crossref","first-page":"327","DOI":"10.2165\/00128071-200506050-00006","article-title":"Treatment of pemphigus vulgaris","volume":"6","author":"Yeh","year":"2005","journal-title":"Am. J. Clin. Dermatol."},{"key":"10.1016\/j.intimp.2019.04.031_bb0045","series-title":"A Review on Pemphigus Vulgaris: Rare but a Severe Auto Immune Disorder","author":"Mishra","year":"2013"},{"issue":"17","key":"10.1016\/j.intimp.2019.04.031_bb0050","doi-asserted-by":"crossref","first-page":"1772","DOI":"10.1056\/NEJMoa062930","article-title":"Treatment of pemphigus vulgaris with rituximab and intravenous immune globulin","volume":"355","author":"Ahmed","year":"2006","journal-title":"N. Engl. J. Med."},{"issue":"3","key":"10.1016\/j.intimp.2019.04.031_bb0055","first-page":"4","article-title":"Advances in pemphigus therapy","volume":"13","author":"Prajapati","year":"2008","journal-title":"Skin Therapy Lett."},{"issue":"4","key":"10.1016\/j.intimp.2019.04.031_bb0060","first-page":"246","article-title":"Epidemiology of autoimmune bullous diseases and therapeutic modalities during a 10\u202fyear period in Iran","volume":"22","author":"Jowkar","year":"2014","journal-title":"Acta Dermatovenerol. Croat."},{"issue":"1","key":"10.1016\/j.intimp.2019.04.031_bb0065","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1186\/s13023-015-0263-4","article-title":"Prediction of survival for patients with pemphigus vulgaris and pemphigus foliaceus: a retrospective cohort study","volume":"10","author":"Baican","year":"2015","journal-title":"Orphanet J. Rare Dis."},{"issue":"6","key":"10.1016\/j.intimp.2019.04.031_bb0070","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1111\/j.1365-4632.2006.02766.x","article-title":"Healing effect of Pilocarpine gel 4% on skin lesions of pemphigus vulgaris","volume":"45","author":"Iraji","year":"2006","journal-title":"Int. J. Dermatol."},{"issue":"2","key":"10.1016\/j.intimp.2019.04.031_bb0075","doi-asserted-by":"crossref","first-page":"145","DOI":"10.4103\/0019-5154.80403","article-title":"Scoring systems in pemphigus","volume":"56","author":"Grover","year":"2011","journal-title":"Indian J. Dermatol."},{"issue":"4","key":"10.1016\/j.intimp.2019.04.031_bb0080","first-page":"325","article-title":"Targeted therapies in rheumatoid arthritis: focus on rituximab","volume":"1","author":"Teng","year":"2007","journal-title":"Biologics Targets Ther."},{"issue":"1","key":"10.1016\/j.intimp.2019.04.031_bb0085","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1002\/art.20718","article-title":"Induction of remission by B lymphocyte depletion in eleven patients with refractory antineutrophil cytoplasmic antibody\u2013associated vasculitis","volume":"52","author":"Keogh","year":"2005","journal-title":"Arthritis Rheum."},{"issue":"2","key":"10.1016\/j.intimp.2019.04.031_bb0090","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1002\/art.20849","article-title":"Rituximab in the treatment of dermatomyositis: an open-label pilot study","volume":"52","author":"Levine","year":"2005","journal-title":"Arthritis Rheum."},{"issue":"1","key":"10.1016\/j.intimp.2019.04.031_bb0095","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.clim.2006.08.016","article-title":"Treatment with rituximab affects both the cellular and the humoral arm of the immune system in patients with SLE","volume":"122","author":"Vallerskog","year":"2007","journal-title":"Clin. Immunol."},{"issue":"4","key":"10.1016\/j.intimp.2019.04.031_bb0100","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1002\/art.27314","article-title":"Effectiveness of rituximab treatment in primary Sj\u00f6gren's syndrome: a randomized, double-blind, placebo-controlled trial","volume":"62","author":"Meijer","year":"2010","journal-title":"Arthritis Rheum."},{"issue":"2","key":"10.1016\/j.intimp.2019.04.031_bb0105","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1111\/j.1365-2133.2005.06740.x","article-title":"Long-standing remission of recalcitrant juvenile pemphigus vulgaris after adjuvant therapy with rituximab","volume":"153","author":"Schmidt","year":"2005","journal-title":"Br. J. Dermatol."},{"issue":"3","key":"10.1016\/j.intimp.2019.04.031_bb0110","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1111\/j.1365-2133.2005.06651.x","article-title":"Anti-CD20 monoclonal antibody (rituximab) in the treatment of pemphigus","volume":"153","author":"Arin","year":"2005","journal-title":"Br. J. Dermatol."},{"issue":"7","key":"10.1016\/j.intimp.2019.04.031_bb0115","article-title":"Anti-CD20 monoclonal antibody (rituximab) in the treatment of autoimmune diseases. Successful result in refractory pemphigus vulgaris: report of a case","volume":"88","author":"Virgolini","year":"2003","journal-title":"Haematologica"},{"issue":"1","key":"10.1016\/j.intimp.2019.04.031_bb0120","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1111\/j.1365-2133.2012.10902.x","article-title":"Intralesional rituximab in the treatment of indolent primary cutaneous B-cell lymphomas: an epidemiological observational multicentre study. The Spanish Working Group on Cutaneous Lymphoma","volume":"167","author":"Pe\u00f1ate","year":"2012","journal-title":"Br. J. Dermatol."},{"issue":"8","key":"10.1016\/j.intimp.2019.04.031_bb0125","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1001\/jamadermatol.2014.3674","article-title":"Intralesional rituximab in the treatment of refractory oral pemphigus vulgaris","volume":"151","author":"Vinay","year":"2015","journal-title":"JAMA Dermatol."},{"issue":"10","key":"10.1016\/j.intimp.2019.04.031_bb0130","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1111\/j.1468-3083.2010.03610.x","article-title":"Adjuvant triamcinolone acetonide injections in oro-pharyngeal pemphigus vulgaris","volume":"24","author":"Mignogna","year":"2010","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"10.1016\/j.intimp.2019.04.031_bb0135","first-page":"365","article-title":"Triamcinolone acetonide for rare ocular manifestations of pemphigus vulgaris: a case report","volume":"4","author":"Kozeis","year":"2010","journal-title":"Clin. Ophthalmol."}],"container-title":["International Immunopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576919303029?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576919303029?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,7,5]],"date-time":"2019-07-05T03:32:02Z","timestamp":1562297522000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1567576919303029"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,8]]},"references-count":27,"alternative-id":["S1567576919303029"],"URL":"https:\/\/doi.org\/10.1016\/j.intimp.2019.04.031","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.735765261.793560670","asserted-by":"object"}]},"ISSN":["1567-5769"],"issn-type":[{"value":"1567-5769","type":"print"}],"subject":[],"published":{"date-parts":[[2019,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Comparison between the efficacy of intralesional rituximab versus intralesional triamcinolone in the treatment refractory Pemphigus Vulgaris lesions: A randomized clinical trial","name":"articletitle","label":"Article Title"},{"value":"International Immunopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.intimp.2019.04.031","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}